Mark Rothera

Chief Commercial Officer

Back to Speakers

Mark Rothera is responsible for establishing the global strategy and footprint to commercialize PTC’s novel therapeutics for the treatment of a range of devastating rare diseases. Mark has spent 25 years in the BioPharmaceutical sector of which the last 16 have been spent pre-launching and launching Orphan Drugs internationally for rare diseases such as Duchenne Muscular Dystrophy, Cystic Fibrosis, Hunder Syndrome, Hereditary Angioedema and Gaucher’s Disease. Mark has built international operations from the very earliest stages at PathoGeneis, Chiron BioPharmacetucals, Shire Human Genetic Therapies and currently PTC Therapeutics. A patient-centred approach has motivated Mark and his teams to enable patients to have access to therapy as early as possible through existing and innovative early access mechanisms. Mark has been a board member of the UK Bio Industry Association, has a Masters in Natural Science from Cambridge University and an MBA from INSEAD